Heterozygous Prothrombin Mutation-Associated Thrombophilia

Abstract

Background Venous thromboembolism (VTE) is predisposed by thrombotic mutations in patients with hereditary thrombophilia. Although prothrombin deficiencies caused by homozygous or compound heterozygous mutations are associated with bleeding diathesis, rare cases have shown a correlation between heterozygous prothrombin mutations and thrombosis.

Materials and Methods We surveyed genetic variants involved in thrombosis and hemostasis in 347 patients with unprovoked VTE or having a positive family history of thrombosis. For patients identified with heterozygous prothrombin mutations, we conducted family investigations and performed a thrombin generation test (TGT) to elucidate the thrombotic risk. Novel mutants were expressed and subjected to functional assays to clarify the underlying thrombotic mechanisms.

Results Heterozygous prothrombin mutations were identified in 3.5% of patients (12/347), including three novel mutations Phe382Ser, Phe382Leu, and Asp597Tyr found in one patient each, as well as previously reported Arg541Trp mutation in four patients and Arg596Gln mutation in five patients. A total of 42 mutation carriers were identified within the 12 pedigrees, among whom 64.3% (27/42) had experienced thrombotic events. TGT results demonstrated hypercoagulability for carriers of the five mutations, with Arg596Gln showing the highest thrombin generation potential followed by Arg541Trp. The Phe382-associated mutations severely impaired thrombomodulin-binding ability of thrombin, resulting in obviously reduced protein C (PC) activation. The Asp597Tyr mutation exhibited a mild reduction in both inactivation by antithrombin and PC activation reactions.

Conclusion The presence of heterozygous prothrombin mutations represents a potential genetic predisposition for VTE. All thrombosis-associated mutations potentiate coagulation activity by either conferring antithrombin resistance and/or impairing PC pathway activity.

Keywords

prothrombin - mutations - thrombosis

Authors' Contribution

J.D. and W.W. designed and supervised the study; W.W. and X.W. wrote the manuscript; X.W., L.L., X.H., and Q.D. collected clinical data of associated patients; Z.L. and P.J. performed functional experiments and analyzed data; P.J., Y.L., and G.X. performed thrombophilia screening tests; Y.L. and X.W. prepared recombinant proteins.

^* These authors contributed equally to this work.

Publication History

Received: 03 May 2024

Accepted: 23 June 2024

Accepted Manuscript online:
24 June 2024

Article published online:
02 July 2024

• References

• 1 Martinelli I, De Stefano V, Mannucci PM. Inherited risk factors for venous thromboembolism. Nat Rev Cardiol 2014; 11 (03) 140-156
• 2 Simioni P, Tormene D, Tognin G. et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 361 (17) 1671-1675
• 3 Wu W, Xiao L, Wu X. et al. Factor IX alteration p.Arg338Gln (FIX Shanghai) potentiates FIX clotting activity and causes thrombosis. Haematologica 2021; 106 (01) 264-268
• 4 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369 (6475) 64-67
• 5 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88 (10) 3698-3703
• 6 Miyawaki Y, Suzuki A, Fujita J. et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012; 366 (25) 2390-2396
• 7 Wu X, Dai J, Xu X. et al. Prothrombin Arg541Trp mutation leads to defective PC (protein C) pathway activation and constitutes a novel genetic risk factor for venous thrombosis. Arterioscler Thromb Vasc Biol 2020; 40 (02) 483-494
• 8 Bulato C, Radu CM, Campello E. et al. New prothrombin mutation (Arg596Trp, Prothrombin Padua 2) associated with venous thromboembolism. Arterioscler Thromb Vasc Biol 2016; 36 (05) 1022-1029
• 9 Wu X, Li L, Ding Q, Wang X, Wu F, Wu W. Screening and functional exploration of prothrombin Arg596 related mutations in Chinese venous thromboembolism patients. J Clin Pathol 2018; 71 (07) 614-619
• 10 Zhang Z, Li C, Wu F. et al. Genomic variations of the mevalonate pathway in porokeratosis. eLife 2015; 4: e06322
• 11 Lu Y, Villoutreix BO, Biswas I, Ding Q, Wang X, Rezaie AR. Antithrombin resistance rescues clotting defect of homozygous prothrombin-Y510N dysprothrombinemia. Thromb Haemost 2022; 122 (05) 679-691
• 12 Rezaie AR. Reactivities of the S2 and S3 subsite residues of thrombin with the native and heparin-induced conformers of antithrombin. Protein Sci 1998; 7 (02) 349-357
• 13 Ding Q, Yang L, Dinarvand P, Wang X, Rezaie AR, Protein C. Protein C Thr315Ala variant results in gain of function but manifests as type II deficiency in diagnostic assays. Blood 2015; 125 (15) 2428-2434
• 14 Crawley JT, Zanardelli S, Chion CK, Lane DA. The central role of thrombin in hemostasis. J Thromb Haemost 2007; 5 (Suppl. 01) 95-101
• 15 Lavigne-Lissalde G, Sanchez C, Castelli C. et al. Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. J Thromb Haemost 2010; 8 (05) 942-949
• 16 Lancellotti S, De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost 2009; 35 (04) 367-381
• 17 Ding Q, Yang L, Zhao X, Wu W, Wang X, Rezaie AR. Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation. Thromb Haemost 2017; 117 (03) 479-490
• 18 Sivasundar S, Oommen AT, Prakash O. et al. Molecular defect of ‘Prothrombin Amrita’: substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding loop of prothrombin. Blood Cells Mol Dis 2013; 50 (03) 182-183
• 19 Yamamoto J, Yamamoto M, Takano K. et al. Venous thromboembolism is caused by prothrombin p.Arg541Trp mutation in Japanese individuals. Hum Genome Var 2021; 8 (01) 13
• 20 Takagi Y, Murata M, Kozuka T. et al. Missense mutations in the gene encoding prothrombin corresponding to Arg596 cause antithrombin resistance and thrombomodulin resistance. Thromb Haemost 2016; 116 (06) 1022-1031
• 21 Li W, Johnson DJ, Esmon CT, Huntington JA. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 2004; 11 (09) 857-862
• 22 Di Cera E, Guinto ER, Vindigni A. et al. The Na+ binding site of thrombin. J Biol Chem 1995; 270 (38) 22089-22092
• 23 Pineda AO, Zhang E, Guinto ER, Savvides SN, Tulinsky A, Di Cera E. Crystal structure of the thrombin mutant D221A/D222K: the Asp222:Arg187 ion-pair stabilizes the fast form. Biophys Chem 2004; 112 (2-3): 253-256
• 24 Huntington JA. How Na+ activates thrombin–a review of the functional and structural data. Biol Chem 2008; 389 (08) 1025-1035
• 25 Hall SW, Nagashima M, Zhao L, Morser J, Leung LL. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. J Biol Chem 1999; 274 (36) 25510-25516
• 26 Huntington JA. Molecular recognition mechanisms of thrombin. J Thromb Haemost 2005; 3 (08) 1861-1872
• 27 Djordjevic V, Kovac M, Miljic P. et al. A novel prothrombin mutation in two families with prominent thrombophilia–the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost 2013; 11 (10) 1936-1939